Dr Lal PathLabs

October 26, 2021

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Intimation under Regulation 30(2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please take note that the Board of Directors of the Company in their meeting held on Tuesday i.e. October 26, 2021, approved acquisition of 100% stake in Suburban Diagnostics (India) Private Limited from its existing shareholders.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in the **Annexure** attached to this letter.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head

Dr. Lal PathLabs Limited

Encl: As above

Classification: Internal

Annexure

Sr. No.	Particulars in respect of the Event	Details/ Information of the Event
1.	Name of the target entity, details in brief such as size, turnover etc.	**Name:** Suburban Diagnostics (India) Private Limited **Turnover (in INR Mn)**: FY 2018-19 – 1,493 FY 2019-20 – 1,699 FY 2020-21 – 2,947
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No, the proposed acquisition does not fall within the ambit of related party transaction(s).
3.	Industry to which the entity being acquired belongs.	Healthcare/ Diagnostics
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To strengthen the Company's presence in the western part of the country / State of Maharashtra
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government approvals required
6.	Indicative time period for completion of the acquisition	Within 1 month
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	INR 9,250 million plus certain performance linked payments capped at INR 2,250 million, subject to certain adjustments.

Classification: Internal

9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Acquisition of 100% stake from its existing shareholders.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	Suburban Diagnostics (India) Private Limited was incorporated on June 06, 2002 in the State of Maharashtra. Suburban Diagnostics (India) Private Limited is engaged in business of establishing, maintaining, running and managing diagnostic centres, radiology centres, cardiology centres including E.C.G. centres, X-Ray clinics, ultrasound centres, pathology laboratories, and centers for providing preventive health check-ups in India. **Turnover:** As mentioned in Clause 1 above.

For Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head

Dr. Lal PathLabs Limited

Classification: Internal